Cerebellar type 1 metabotropic glutamate receptor availability decreases with disease progression in spinocerebellar ataxia type 6.
Autor: | Miura Y; Department of Neurology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan., Ishibashi K; Department of Neurology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan; Diagnostic Neuroimaging Research, Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan. Electronic address: ishibashi@pet.tmig.or.jp. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of the neurological sciences [J Neurol Sci] 2024 Dec 15; Vol. 467, pp. 123321. Date of Electronic Publication: 2024 Nov 22. |
DOI: | 10.1016/j.jns.2024.123321 |
Abstrakt: | Background: Imaging of type 1 metabotropic glutamate receptor (mGluR1), which is predominantly expressed in Purkinje cells, is currently possible using positron emission tomography (PET). We have previously shown that cerebellar mGluR1 availability decreases in patients with cerebellar ataxia and that the degree of ataxia is related to the magnitude of cerebellar mGluR1 availability. This study presents the longitudinal changes in cerebellar mGluR1 availability after an interval of years in patients with spinocerebellar ataxia type 6 (SCA6). Methods: Three patients with SCA6 underwent baseline and follow-up mGluR1 PET and magnetic resonance imaging (MRI) at intervals of 2-6 years. The volume-of-interest was placed on the cerebellum. The binding potential (BP Results: The cerebellar BP Conclusions: This study shows that cerebellar mGluR1 availability decreases with disease progression in SCA6, and that mGluR1 imaging is likely superior to MRI in identifying small changes in the cerebellum. Therefore, mGluR1 imaging can be used as a specific biomarker for monitoring cerebellar function. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |